Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 2/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27192125 | 0.83 | IMPDH2 (0.33) | SLC22A12IMPDH2 | |
| SCHEMBL17981127 | 0.81 | IMPDH2 (0.33) | IMPDH2 | |
| SCHEMBL17981072 | 0.73 | CYP1A2 (0.41) | IMPDH2LMNAGAAHPGD | |
| SCHEMBL29923537 | 0.73 | CYP1A2 (0.41) | IMPDH2LMNAGAAHPGD | |
| SCHEMBL18105506 | 0.71 | EGFR (0.46) | PLAUIMPDH2MEN1LMNAKMT2A | |
| SCHEMBL3128980 | 0.70 | UGT2B7 (0.58) | UGT2B7PLGPLAUCYP11B1CYP11B2 | |
| SCHEMBL30133773 | 0.70 | UGT2B7 (0.58) | UGT2B7PLGPLAUCYP11B1CYP11B2 | |
| SCHEMBL30188824 | 0.69 | TDP1 (0.37) | CYP11B1CYP11B2IMPDH2 | |
| SCHEMBL17981146 | 0.69 | TDP1 (0.37) | CYP11B1CYP11B2IMPDH2 | |
| SCHEMBL27191917 | 0.69 | NOS1 (0.37) | CYP11B1CYP11B2IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11213520-B2 | Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-01-04 | — | — | US | disclosed |
| EP-3464267-B1 | NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-09-23 | — | — | EP | disclosed |
| US-20190290637-A1 | NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11213520-B2 | Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors | CDK9, CDK19, CDK8 | UGT2B7 1836/4885CDK8 3/4885CCNC 39/4885 |
| US-20190290637-A1 | NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | CDK9, CDK19, CDK8 | UGT2B7 2006/4885CDK8 3/4885CCNC 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.